# Second-line Treatment of Primary Autoimmune Hemolytic Anemia

> **NCT05057468** · PHASE3 · RECRUITING · sponsor: **Assiut University** · enrollment: 30 (estimated)

## Conditions studied

- Primary Autoimmune Hemolytic Anemia

## Interventions

- **DRUG:** Cyclosporine
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT05057468
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-20
- **Primary completion:** 2026-11-01
- **Final completion:** 2026-11-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05057468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05057468, "Second-line Treatment of Primary Autoimmune Hemolytic Anemia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05057468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*